

## A Phase II, Open Label, Two Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination with Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (OPTIMUM Trial) Protocol Number: MIBG 2014-01

**Status:** Recruiting

**Eligibility Criteria**

**Conditions & Interventions**

### More Information

**Description:** This will be a Phase II, two-arm, nonrandomized, non-comparative, open-label study in participants  $\geq 1$  year of age with iobenguane avid, recurrent or progressive high-risk neuroblastoma. Participants not eligible for vorinostat treatment may receive 131I-MIBG as monotherapy.

**Contact(s):** Allison Fullenkamp - fulle631@umn.edu

**Principal Investigator:** Emily Greengard

#### IRB

**Number:** STUDY00005792

**System ID:** 24372

---

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.